Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ
Currency in USD
Disclaimer
59.08
-0.24(-0.40%)
Closed
After Hours
59.080.00(0.00%)
Day's Range
58.6959.93
52 wk Range
57.7797.65
Prev. Close
59.32
Open
59.28
Day's Range
58.69-59.93
52 wk Range
57.77-97.65
Volume
94,511
Average Vol. (3m)
96,115
1-Year Change
-27.17%
Shares Outstanding
17,355,257
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
112.67
Upside +90.70%

People Also Watch

15.60
OMI
-0.64%
31.64
CORT
-0.91%
17.11
ASB
-0.93%
59.80
USNA
-0.96%

Ligand Pharmaceuticals Incorporated Company Profile

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. The Company’s Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. The Company’s products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and Other. Kyprolis is formulated with Ligand’s Captisol technology. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. Its other products include Pneumosil, Rylaze, Nexterone, Veklury, Zulresso, and Noxafil-IV.

Employees
154

Income Statement